Hikma debuts generic Buprenex

Hikma is releasing buprenorphine hydrochloride injection, in a dosage strength of 0.3mg/mL.

The product is the generic of Reckitt Benckiser Healthcare’s Buprenex.

Buprenorphine HCl injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate.

“We are committed to providing doctors and patients with the medicines they need and are pleased to launch Buprenorphine HCl vials, an important medicine used for pain management,” said Riad Mishlawi, Hikma president of injectables.

Buprenorphine hydrochloride injection, 0.3mg/mL, had a market value of approximately $16 million for the 12 months ending February 2020, according to IQVIA.